CompletedPhase 3NCT05001737
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Brian Jamieson, MDSwedish Orphan Biovitrum
- Intervention
- Emapalumab(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 80 years · All sexes
- Timeline
- 2021 – 2025
Study locations (30)
- UAB Hospital, Birmingham, Alabama, United States
- UCLA Health, Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Abigail Wexner Research Institute, Columbus, Ohio, United States
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Universitair Ziekenhuis Leuven, Leuven, Belgium
- Alberta Children's Hospital, Calgary, Canada
- University of Calgary, Calgary, Canada
- Centre Hospitalier de l'Université de Montréal, Montreal, Canada
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
- Hospital for sick children, Toronto, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05001737 on ClinicalTrials.govOther trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07525466Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)Beijing Tongren Hospital
- RECRUITINGPHASE4NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07488728Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisBeijing Children's Hospital
- RECRUITINGPHASE2NCT06160791Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Jerry Lee, MD, MSc, MPhil
- ACTIVE NOT RECRUITINGNCT06587191Emapalumab Efficacy in Children With Primary Hemophagocytic LymphohistiocytosisFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGNCT06339177Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE StudyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06585124Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06614998Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective StudyThe Affiliated Hospital of Xuzhou Medical University
See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease →